| Molecular Formula | C11H11NO3 |
| Molar Mass | 205.21 |
| Melting Point | 157-158℃ |
| Solubility | Soluble in DMSO (up to 30 mg/ml). |
| Appearance | solid |
| Color | White |
| Storage Condition | Sealed in dry,2-8°C |
| Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. |
| In vitro study | VGX-1027 significantly inhibited IL-1β/IFN-γ induced TNF-α and nitrite accumulation, and significantly increased cell survival by interfering with the toxic effects of cytokines. VGX-1027 inhibition of intestinal bacterial antigen-reactive CD4 CD25 -T cell proliferation in vitro. |
| In vivo study | VGX-1027 prevents the development of spontaneous type I diabetes in NOD mice and counteracts the acceleration of diabetes induced by cyclophosphamide challenge or adoptive transfer of diabetic splenocytes in NOD mice. VGX-1027 also reduced the clinical signal of diabetes induced by MLD-STZ and inhibited histopathological changes in the pancreas. VGX-1027 inhibits the clinical, histological, and immunological development of DNBS-induced colitis in CD1 mice. In the NZB/ NZW F1 model of systemic lupus erythematosus (SLE), VGX-1027 improved symptoms of the disease, improved survival, and improved clinical and histopathological signals. |
| Hazard Symbols | Xn - Harmful![]() |
| Risk Codes | R22 - Harmful if swallowed R43 - May cause sensitization by skin contact |
| Safety Description | 36/37 - Wear suitable protective clothing and gloves. |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 4.873 ml | 24.365 ml | 48.731 ml |
| 5 mM | 0.975 ml | 4.873 ml | 9.746 ml |
| 10 mM | 0.487 ml | 2.437 ml | 4.873 ml |
| 5 mM | 0.097 ml | 0.487 ml | 0.975 ml |